<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01995890</url>
  </required_header>
  <id_info>
    <org_study_id>TVPEI</org_study_id>
    <nct_id>NCT01995890</nct_id>
  </id_info>
  <brief_title>Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes</brief_title>
  <official_title>Effect of Nepafenac Eye Drops on Intraocular Pressure - a Randomized Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr T V Patel Eye Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr T V Patel Eye Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Nevanac product information insert says that it can cause increase in eye pressure in
      5-10% of patients. There is very little published literature on the effect of topical
      Nepafenac eye drops on eye pressure in normal people. The purpose of our study is to report
      this effect with a working hypothesis that there is no increase in eye pressure following use
      of Nepafenac eye drops.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>4 weeks</time_frame>
    <description>Intraocular pressure elevation of more than 4 mmHg from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Intraocular pressure elevation of more than 4 mmHg from baseline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">327</enrollment>
  <condition>Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>nepafenac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nepafenac 0.1% eye drops, 3 times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention in the control arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nepafenac</intervention_name>
    <arm_group_label>nepafenac</arm_group_label>
    <other_name>Nevanac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Best corrected visual acuity better than 20/80 in both eyes

          -  Intraocular pressure â‰¤21 mmHg in both eyes

          -  Open angles on 4 mirror gonioscopy without indentation

          -  Normal optic disc on stereoscopic examination and photographs

        Exclusion Criteria:

          -  Change in the systemic medication profile during the course of the study

          -  Allergy to nepafenac molecule

          -  Corneal thinning/corneal infections

          -  Any intraocular surgery in past 3 months

          -  Pregnancy or those planning to conceive

          -  Breast feeding patients

          -  Unwillingness to participate in the trial

          -  Concomitant use of any other ocular drug (except artificial tears)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paaraj R Dave, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TV Patel Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr TV Patel Eye Insititute</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70.</citation>
    <PMID>10850857</PMID>
  </reference>
  <results_reference>
    <citation>Chiba T, Kashiwagi K, Chiba N, Tsukahara S. Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2006 Mar;90(3):314-7.</citation>
    <PMID>16488953</PMID>
  </results_reference>
  <results_reference>
    <citation>Warren KA, Fox JE. Topical nepafenac as an alternate treatment for cystoid macular edema in steroid responsive patients. Retina. 2008 Nov-Dec;28(10):1427-34. doi: 10.1097/IAE.0b013e31817e7ead.</citation>
    <PMID>18664937</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <last_update_submitted>November 22, 2013</last_update_submitted>
  <last_update_submitted_qc>November 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nepafenac eye drops</keyword>
  <keyword>intraocular pressure</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Nepafenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

